{"database": "lobbying", "table": "lobbying_activities", "rows": [[2638326, "3eb566f6-32ba-45b5-98bd-2653619b6878", "Q2", "RED+BLUE STRATEGIES", 400693064, "COHERUS BIOSCIENCES", 2021, "second_quarter", "PHA", "S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. \n\nIssues and policies that incent companies to increase their US footprint and adopt Made in America business practices. \n\nPolicies to help grow the biosimilars marketplace in the United States. \n\nPolicies focused on improving cancer care through access to affordable treatments.", "HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", 60000, null, 0, 0, "2021-07-15T15:04:59.790000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2638326"], "units": {}, "query_ms": 0.36048307083547115, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}